BioPorto Divests Antibody Business for $10.5M to Focus on NGAL Biomarker Development
核心洞察
BioPorto A/S (搜索) completed the divestment of its antibody business to Janel Life Sciences LLC (搜索) for $10.5 million, with $9 million paid at closing and $1.5 million in potential earn-outs over three years.
The strategic transaction allows BioPorto to strengthen its focus on driving market adoption of its NGAL (搜索) biomarker for acute kidney injury (搜索) diagnosis and unlocks capital for long-term growth.
Following the divestment, BioPorto expects to cover projected spending through the first half of 2028 and aspires to achieve cash flow positivity during that period without additional equity funding.
BioPorto A/S (搜索) announced the successful completion of its antibody business divestment to Janel Life Sciences LLC (搜索), a subsidiary of the Janel Corporation (搜索), for a total consideration of USD 10.5 million. The transaction, which closed simultaneously with signing on April 8, 2026, represents a strategic milestone in the Danish diagnostics company's efforts to concentrate resources on its core NGAL (搜索) biomarker technology.
The deal structure includes USD 9 million paid at closing, with an additional USD 1.5 million available as earn-out payments over the next three years, contingent on achieving specific commercial milestones. The divested assets comprise research-use-only antibodies and clones, inventory, and related contracts.
Strategic Refocus on NGAL Technology
CEO Carsten Buhl emphasized the transaction's strategic importance, stating: "We are very pleased to have completed this transaction. It marks an important strategic step in strengthening focus on our core business area with the greatest growth potential. By divesting non-core assets, we unlock capital and organizational capacity to accelerate growth as outlined in our 'Forward' strategy plan."
The divestment aligns with BioPorto's strategy to drive market adoption of its NGAL (搜索) biomarker, which is designed to aid in risk assessment and diagnosis of Acute Kidney Injury (搜索) (AKI). The company describes AKI as a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. NGAL testing enables physicians to identify patients at risk of AKI more rapidly than current standard of care measurements, facilitating earlier intervention and more tailored patient management strategies.
Financial Impact and Updated Guidance
The transaction enhances BioPorto's financial flexibility and provides funding to support continued progress toward sustainable positive cash flow. With the divestment proceeds, the company expects to cover current projected spending through the first half of 2028 and aspires to become cash flow positive during that period without requiring additional equity funding, assuming successful execution of previously communicated strategic milestones.
BioPorto has revised its 2026 financial guidance following the divestment. Total revenue expectations have been adjusted from 48-58 million DKK to 38-48 million DKK, while total NGAL (搜索) revenue projections remain unchanged at 33-42 million DKK. The adjusted EBITDA loss guidance has increased from 50-60 million DKK to 58-68 million DKK.
Long-term Aspirations Adjusted
The company has also updated its aspirations toward 2028. Total revenue projections have been revised from 150-200 million DKK to 135-185 million DKK, while maintaining the target of at least 15% adjusted EBITDA margin. The timeline for achieving cash flow positivity has been extended from the second half of 2027 to the first half of 2028.
The transaction will result in an accounting gain of approximately DKK 54 million on EBITDA and net profits, though with no impact on adjusted EBITDA, using a USD/DKK exchange rate of 6.4.
Company Background and Market Position
BioPorto operates as an in vitro diagnostics company focused on developing actionable kidney biomarkers to help clinicians make changes in patient management. The company leverages its expertise in assay development to create products addressing significant unmet medical needs where its tests can improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The company's flagship NGAL (搜索)-based products are marketed under applicable registrations, including CE mark in several countries worldwide and FDA clearance for ProNephro AKI (搜索) (NGAL) for pediatric use in the United States. BioPorto maintains facilities in Copenhagen, Denmark, and Boston, Massachusetts, with shares listed on the Nasdaq Copenhagen stock exchange.